A phase II trial of busulfan, melphalan, and fludarabine with peri-transplant palifermin, followed by a T-cell depleted hematopoietic stem cell transplant from HLA [human leukocyte antigen] matched or mismatched related or unrelated donors in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Trial Profile

A phase II trial of busulfan, melphalan, and fludarabine with peri-transplant palifermin, followed by a T-cell depleted hematopoietic stem cell transplant from HLA [human leukocyte antigen] matched or mismatched related or unrelated donors in patients with advanced myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2017

At a glance

  • Drugs Palifermin (Primary) ; Antithymocyte globulin; Busulfan; Fludarabine; Melphalan
  • Indications Acute myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
    • 07 Mar 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.
    • 15 Dec 2015 Planned End Date changed from 1 Feb 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top